OnKure Therapeutics, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $159.6M
- Price
- $3.94
- % Change (Daily % change from the live per-ticker quote feed.)
- +0.25%
- Volume
- 38.4K
About
OnKure, Inc., established in 2011 and based in Boulder, Colorado, operates as a biopharmaceutical company primarily engaged in the creation and advancement of precise therapeutic agents for cancer. A core area of their research centers on developing highly selective inhibitors for histone deacetylases. Their current pipeline features OKI-179, an inhibitor specifically engineered to combat a wide spectrum of malignancies, including both blood-related cancers and solid tumor formations.
Quick stats
Shares outstanding40.5M
Computed float24.9M
Float / shares61.5%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001637715
AI Summary
AI-generated1/7
standardbullishoperations update
OnKure Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights
OnKure reported $176.4 million in cash, cash equivalents, and marketable securities as of June 30, 2026, which it expects will fund operations into 2029.
The company continues IND-enabling activities for its lead candidates, OKI-345 for breast cancer and OKI-355 for vascular anomalies, with IND submissions planned for the first half of 2027.
For the second quarter, R&D expenses were $12.6 million and G&A expenses were $4.3 million, resulting in a net loss of $15.3 million, or $0.31 per share.